ABBVIE Company Profile

✉ Email this page to a colleague

What is the competitive landscape for ABBVIE, and when can generic versions of ABBVIE drugs launch?

ABBVIE has one hundred and thirty-eight approved drugs.

There are two hundred and twenty-nine US patents protecting ABBVIE drugs.

There are two thousand seven hundred and twenty patent family members on ABBVIE drugs in sixty-six countries and three hundred and ninety-one supplementary protection certificates in nineteen countries.

Summary for ABBVIE

International Patents:	2720
US Patents:	229
Tradenames:	124
Ingredients:	99
NDAs:	138
Drug Master File Entries:	1
Patent Litigation for ABBVIE:	See patent lawsuits for ABBVIE

Drugs and US Patents for ABBVIE

+ Get email alerts for changes to this table

Glossary

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Abbvie	DALVANCE	dalbavancin hydrochloride	POWDER;INTRAVENOUS	021883-001	May 23, 2014		RX	Yes	Yes	6,900,175	⤷ Try a Trial				⤷ Try a Trial
Abbvie	VENCLEXTA	venetoclax	TABLET;ORAL	208573-001	Apr 11, 2016		RX	Yes	No	11,413,282	⤷ Try a Trial				⤷ Try a Trial
Abbvie	MAVYRET	glecaprevir; pibrentasvir	TABLET;ORAL	209394-001	Aug 3, 2017		RX	Yes	Yes	11,246,866*PED	⤷ Try a Trial			Y	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>TE	>Type	>RLD	>RS	>Patent No.	>Patent Expiration	>Product	>Substance	>Delist Req.	>Exclusivity Expiration

Expired US Patents for ABBVIE

Subscribe to access the full database, or Try a Trial
Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	Patent No.	Patent Expiration
Abbvie	NIASPAN	niacin	TABLET, EXTENDED RELEASE;ORAL	020381-004	Jul 28, 1997	6,129,930	⤷ Try a Trial
Abbvie	OZURDEX	dexamethasone	IMPLANT;INTRAVITREAL	022315-001	Jun 17, 2009	9,592,242	⤷ Try a Trial
Abbvie	CARAFATE	sucralfate	TABLET;ORAL	018333-001	Approved Prior to Jan 1, 1982	3,432,489	⤷ Try a Trial
>Applicant	>Tradename	>Generic Name	>Dosage	>NDA	>Approval Date	>Patent No.	>Patent Expiration

Paragraph IV (Patent) Challenges for ABBVIE drugs

Drugname	Dosage	Strength	Tradename	Submissiondate
➤ Subscribe	Injection	400 mg/vial and 600 mg/vial	➤ Subscribe	2014-10-29
➤ Subscribe	Tablets	5 mg/200 mg	➤ Subscribe	2005-05-27
➤ Subscribe	Extended-release Tablet	500 mg	➤ Subscribe	2010-12-06
➤ Subscribe	Capsules	14 mg/10 mg and 28 mg/10 mg	➤ Subscribe	2015-05-18
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-23
➤ Subscribe	Extended-release Tablets	500 mg	➤ Subscribe	2005-02-08
➤ Subscribe	Capsules	7 mg/10 mg	➤ Subscribe	2016-09-26
➤ Subscribe	Ophthalmic Solution	0.10%	➤ Subscribe	2006-12-20
➤ Subscribe	Extended-release Tablets	2 mg/180 mg and 2 mg/240 mg	➤ Subscribe	2007-11-09
➤ Subscribe	Oral Solution	80 mg/20 mg per mL	➤ Subscribe	2014-06-19
➤ Subscribe	Ophthalmic Solution	0.2%/0.5%	➤ Subscribe	2008-11-21
➤ Subscribe	Extended-release Tablets	4 mg/ 240 mg	➤ Subscribe	2007-07-24
➤ Subscribe	Tablets	100 mg	➤ Subscribe	2010-12-21
➤ Subscribe	Ophthalmic Solution	0.03%	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	1 mg, 2 mg and 4 mg	➤ Subscribe	2004-10-04
➤ Subscribe	Injection	0.002 mg per mL in 1 mL vial and 0.005 mg per mL in 1 mL and 2 mL vials	➤ Subscribe	2008-11-28
➤ Subscribe	Ophthalmic Solution	0.5%	➤ Subscribe	2010-12-07
➤ Subscribe	Delayed-release Capsules	45 mg	➤ Subscribe	2009-09-02
➤ Subscribe	Tablets	12.5 mg, 25 mg, 50 mg, and 100 mg	➤ Subscribe	2013-01-14
➤ Subscribe	Capsules	4 mcg	➤ Subscribe	2008-08-25
➤ Subscribe	Capsules	5 mg	➤ Subscribe	2005-08-17
➤ Subscribe	Extended-release Capsules	20 mg, 40 mg, 80 mg and 120 mg	➤ Subscribe	2017-07-25
➤ Subscribe	Tablets	48 mg	➤ Subscribe	2008-07-01
➤ Subscribe	Gel	10%	➤ Subscribe	2014-06-19
➤ Subscribe	Injection	10 mg/mL (2 mL)	➤ Subscribe	2018-07-13
➤ Subscribe	Extended-release Capsules	28 mg	➤ Subscribe	2013-06-12
➤ Subscribe	Tablets	2.5 mg/200 mg	➤ Subscribe	2006-02-24
➤ Subscribe	Injection	2 mg/mL, 10 mL vial	➤ Subscribe	2009-08-12
➤ Subscribe	Delayed-release Tablets	800 mg	➤ Subscribe	2011-07-13
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-06-10
➤ Subscribe	Ophthalmic Solution	0.40%	➤ Subscribe	2005-01-28
➤ Subscribe	Tablets	10 mg, 20 mg, and 40 mg	➤ Subscribe	2015-01-21
➤ Subscribe	Extended-release Tablets	250 mg	➤ Subscribe	2004-05-03
➤ Subscribe	Capsules	21 mg/10 mg	➤ Subscribe	2016-09-23
➤ Subscribe	Opthalmic Solution	0.45%	➤ Subscribe	2011-08-24
➤ Subscribe	Extended-release Tablets	7.5 mg and 15 mg	➤ Subscribe	2008-12-22
➤ Subscribe	Tablets	100 mg/25 mg	➤ Subscribe	2008-12-23
➤ Subscribe	Ophthalmic Solution	0.15%	➤ Subscribe	2006-11-03
➤ Subscribe	Extended-release Tablets	1 mg/240 mg	➤ Subscribe	2008-02-20
➤ Subscribe	Capsules	145 mcg and 290 mcg	➤ Subscribe	2016-08-30
➤ Subscribe	Ophthalmic Solution	0.25%	➤ Subscribe	2014-07-30
➤ Subscribe	Tablets	5 mg/80 mg	➤ Subscribe	2017-06-09
➤ Subscribe	Capsules	100 mg	➤ Subscribe	2012-10-31
➤ Subscribe	Ophthalmic Solution	0.01%	➤ Subscribe	2011-04-05
➤ Subscribe	Delayed-release Capsules	400 mg	➤ Subscribe	2014-06-17
➤ Subscribe	Tablets	5 mg and 10 mg	➤ Subscribe	2007-10-16
➤ Subscribe	Capsules	1 mcg and 2 mcg	➤ Subscribe	2008-10-14
➤ Subscribe	Topical Solution	0.03%	➤ Subscribe	2010-05-03
➤ Subscribe	Delayed-release Capsules	135 mg	➤ Subscribe	2009-09-01
➤ Subscribe	Tablets	400 mg and 600 mg	➤ Subscribe	2010-05-10
➤ Subscribe	Gel	7.5%	➤ Subscribe	2017-02-13
➤ Subscribe	Capsules	10 mg and 20 mg	➤ Subscribe	2005-03-30
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg, and 28 mg	➤ Subscribe	2013-08-16
➤ Subscribe	Tablets	145 mg	➤ Subscribe	2007-10-19
➤ Subscribe	Injection	2 mg/mL, 5 mL vial and 10 mg/mL, 20 mL vial	➤ Subscribe	2009-08-04
➤ Subscribe	Suppository	1000 mg	➤ Subscribe	2013-05-24
➤ Subscribe	Extended-release Capsules	7 mg, 14 mg, 21 mg	➤ Subscribe	2013-06-17

International Patents for ABBVIE Drugs

Subscribe to access the full database, or Try a Trial
Country	Patent Number	Estimated Expiration
Germany	202012012956	⤷ Try a Trial
Cyprus	1108656	⤷ Try a Trial
Croatia	P20151389	⤷ Try a Trial
>Country	>Patent Number	>Estimated Expiration

Supplementary Protection Certificates for ABBVIE Drugs

Subscribe to access the full database, or Try a Trial
Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
2203431	247 50008-2015	Slovakia	⤷ Try a Trial	PRODUCT NAME: DASABUVIR (VO FORME MONOHYDRATU SODNEJ SOLI); REGISTRATION NO/DATE: EU/1/14/983/001 20150119
2692346	299 50017-2017	Slovakia	⤷ Try a Trial	PRODUCT NAME: PIBRENTASVIR VO VSETKYCH FORMACH CHRANENYCH ZAKLADNYM PATENTOM; REGISTRATION NO/DATE: EU/1/17/1213 20170728
2666774	CR 2020 00037	Denmark	⤷ Try a Trial	PRODUCT NAME: RELEBACTAM, OPTIONALLY IN THE FORM OF THE MONOHYDRATE, IMIPENEM AND CILASTATIN, OPTIONALLY IN THE FORM OF THE SODIUM SALT; REG. NO/DATE: EU/1/19/1420 20200217
>Patent Number	>Supplementary Protection Certificate	>SPC Country	>SPC Expiration	>SPC Description

Similar Applicant Names

Applicants may be listed under multiple names.
Here is a list of applicants with similar names.

Summary for ABBVIE

Paragraph IV (Patent) Challenges for ABBVIE drugs

Similar Applicant Names

Make Better Decisions: Try a trial or see plans & pricing